6wrz › Citations

High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal strategies for structure-based inhibitor design.

<div class='caption-title'>Overall structure of the nsp16-nsp10 oligomers.</div>
<div class='caption-title'>Detailed representation of nsp16, nsp10, and the heterodimer interface.</div>
<div class='caption-title'>Substrate interactions and catalytic site.</div>
Rosas-Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O, Brunzelle J, Satchell KJF
OpenAccess logo Sci Signal 13 (2020)
Related entries: 6w4h, 6w75, 6wjt, 6wkq, 6wq3, 6wvn

Cited: 99 times
EuropePMC logo PMID: 32994211

Abstract

There are currently no antiviral therapies specific for SARS-CoV-2, the virus responsible for the global pandemic disease COVID-19. To facilitate structure-based drug design, we conducted an x-ray crystallographic study of the SARS-CoV-2 nsp16-nsp10 2'-O-methyltransferase complex, which methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection. We determined the structures for nsp16-nsp10 heterodimers bound to the methyl donor S-adenosylmethionine (SAM), the reaction product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG). We also solved structures for nsp16-nsp10 in complex with the methylated Cap-0 analog m7GpppA and either SAM or SAH. Comparative analyses between these structures and published structures for nsp16 from other betacoronaviruses revealed flexible loops in open and closed conformations at the m7GpppA-binding pocket. Bound sulfates in several of the structures suggested the location of the ribonucleic acid backbone phosphates in the ribonucleotide-binding groove. Additional nucleotide-binding sites were found on the face of the protein opposite the active site. These various sites and the conserved dimer interface could be exploited for the development of antiviral inhibitors.

Reviews - 6wrz mentioned but not cited (2)

  1. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Front Mol Biosci 7 605236 (2020)
  2. Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. Chellapandi P, Saranya S. Med Chem Res 29 1777-1791 (2020)

Articles - 6wrz mentioned but not cited (9)

  1. Structural basis of RNA cap modification by SARS-CoV-2. Viswanathan T, Arya S, Chan SH, Qi S, Dai N, Misra A, Park JG, Oladunni F, Kovalskyy D, Hromas RA, Martinez-Sobrido L, Gupta YK. Nat Commun 11 3718 (2020)
  2. High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal strategies for structure-based inhibitor design. Rosas-Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O, Brunzelle J, Satchell KJF. Sci Signal 13 eabe1202 (2020)
  3. From quantum-derived principles underlying cysteine reactivity to combating the COVID-19 pandemic. Mazmanian K, Chen T, Sargsyan K, Lim C. Wiley Interdiscip Rev Comput Mol Sci 12 e1607 (2022)
  4. 2'-O methylation of RNA cap in SARS-CoV-2 captured by serial crystallography. Wilamowski M, Sherrell DA, Minasov G, Kim Y, Shuvalova L, Lavens A, Chard R, Maltseva N, Jedrzejczak R, Rosas-Lemus M, Saint N, Foster IT, Michalska K, Satchell KJF, Joachimiak A. Proc Natl Acad Sci U S A 118 e2100170118 (2021)
  5. Functional and druggability analysis of the SARS-CoV-2 proteome. Cavasotto CN, Lamas MS, Maggini J. Eur J Pharmacol 890 173705 (2021)
  6. Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16. Minasov G, Rosas-Lemus M, Shuvalova L, Inniss NL, Brunzelle JS, Daczkowski CM, Hoover P, Mesecar AD, Satchell KJF. Sci Signal 14 eabh2071 (2021)
  7. Production of Proteins of the SARS-CoV-2 Proteome for Drug Discovery. Kim C, Mahasenan KV, Bhardwaj A, Wiest O, Chang M, Mobashery S. ACS Omega 6 19983-19994 (2021)
  8. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening. Samdani MN, Morshed N, Reza R, Asaduzzaman M, Islam ABMMK. Mol Divers 27 1067-1085 (2023)
  9. African derived phytocompounds may interfere with SARS-CoV-2 RNA capping machinery via inhibition of 2'-O-ribose methyltransferase: An in silico perspective. Gyebi GA, Ogunyemi OM, Adefolalu AA, Rodríguez-Martínez A, López-Pastor JF, Banegas-Luna AJ, Pérez-Sánchez H, Adegunloye AP, Ogunro OB, Afolabi SO. J Mol Struct 1262 133019 (2022)


Reviews citing this publication (25)

  1. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  2. Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther 7 26 (2022)
  3. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Beyer DK, Forero A. J Mol Biol 434 167265 (2022)
  4. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Wu CR, Yin WC, Jiang Y, Xu HE. Acta Pharmacol Sin 43 3021-3033 (2022)
  5. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. Chiale C, Greene TT, Zuniga EI. Immunol Rev 309 12-24 (2022)
  6. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Moga E, Lynton-Pons E, Domingo P. Front Immunol 13 904686 (2022)
  7. A structural view of the SARS-CoV-2 virus and its assembly. Hardenbrook NJ, Zhang P. Curr Opin Virol 52 123-134 (2022)
  8. COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks. Kgatle MM, Lawal IO, Mashabela G, Boshomane TMG, Koatale PC, Mahasha PW, Ndlovu H, Vorster M, Rodrigues HG, Zeevaart JR, Gordon S, Moura-Alves P, Sathekge MM. Front Immunol 12 752380 (2021)
  9. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW. Chem Rev 122 11287-11368 (2022)
  10. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. Low ZY, Zabidi NZ, Yip AJW, Puniyamurti A, Chow VTK, Lal SK. Viruses 14 1991 (2022)
  11. COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. Chakravarty S. J Proteome Res 20 139-153 (2021)
  12. The Role of Coronavirus RNA-Processing Enzymes in Innate Immune Evasion. Mandilara G, Koutsi MA, Agelopoulos M, Sourvinos G, Beloukas A, Rampias T. Life (Basel) 11 571 (2021)
  13. Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. Zhang C, Yang M. Int J Mol Sci 23 6083 (2022)
  14. The importance of genomic analysis in cracking the coronavirus pandemic. Zella D, Giovanetti M, Cella E, Borsetti A, Ciotti M, Ceccarelli G, D'Ettorre G, Pezzuto A, Tambone V, Campanozzi L, Magheri M, Unali F, Bianchi M, Benedetti F, Pascarella S, Angeletti S, Ciccozzi M. Expert Rev Mol Diagn 21 547-562 (2021)
  15. Structural biology in the time of COVID-19: perspectives on methods and milestones. Lynch ML, Snell EH, Bowman SEJ. IUCrJ 8 335-341 (2021)
  16. CoV-er all the bases: Structural perspectives of SARS-CoV-2 RNA synthesis. Malone B, Campbell EA, Darst SA. Enzymes 49 1-37 (2021)
  17. The Interplay Between Coronavirus and Type I IFN Response. Xue W, Ding C, Qian K, Liao Y. Front Microbiol 12 805472 (2021)
  18. Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. Manan A, Pirzada RH, Haseeb M, Choi S. Int J Mol Sci 23 10716 (2022)
  19. Applications of density functional theory in COVID-19 drug modeling. Ye N, Yang Z, Liu Y. Drug Discov Today 27 1411-1419 (2022)
  20. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  21. The impact of high-resolution structural data on stemming the COVID-19 pandemic. Cox RM, Plemper RK. Curr Opin Virol 49 127-138 (2021)
  22. Accelerating antiviral drug discovery: lessons from COVID-19. von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, Tallarico JA, Lee AA. Nat Rev Drug Discov 22 585-603 (2023)
  23. Coronavirus 2'-O-methyltransferase: A promising therapeutic target. Schindewolf C, Menachery VD. Virus Res 336 199211 (2023)
  24. The role of post-transcriptional regulation in SARS-CoV-2 infection and pathogenicity. Wang X, Chang Z, Zhao T, Zhong W, Shi J, Wang G, Xu X. Front Immunol 14 1256574 (2023)
  25. What do we know about the function of SARS-CoV-2 proteins? Justo Arevalo S, Castillo-Chávez A, Uribe Calampa CS, Zapata Sifuentes D, Huallpa CJ, Landa Bianchi G, Garavito-Salini Casas R, Quiñones Aguilar M, Pineda Chavarría R. Front Immunol 14 1249607 (2023)

Articles citing this publication (63)

  1. Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Lin S, Chen H, Chen Z, Yang F, Ye F, Zheng Y, Yang J, Lin X, Sun H, Wang L, Wen A, Dong H, Xiao Q, Deng D, Cao Y, Lu G. Nucleic Acids Res 49 5382-5392 (2021)
  2. In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors. Singh R, Bhardwaj VK, Sharma J, Purohit R, Kumar S. J Tradit Complement Med 12 35-43 (2022)
  3. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. Peng Q, Peng R, Yuan B, Wang M, Zhao J, Fu L, Qi J, Shi Y. Innovation (Camb) 2 100080 (2021)
  4. High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor. Clyde A, Galanie S, Kneller DW, Ma H, Babuji Y, Blaiszik B, Brace A, Brettin T, Chard K, Chard R, Coates L, Foster I, Hauner D, Kertesz V, Kumar N, Lee H, Li Z, Merzky A, Schmidt JG, Tan L, Titov M, Trifan A, Turilli M, Van Dam H, Chennubhotla SC, Jha S, Kovalevsky A, Ramanathan A, Head MS, Stevens R. J Chem Inf Model 62 116-128 (2022)
  5. Coronaviral RNA-methyltransferases: function, structure and inhibition. Nencka R, Silhan J, Klima M, Otava T, Kocek H, Krafcikova P, Boura E. Nucleic Acids Res 50 635-650 (2022)
  6. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Basu S, Mak T, Ulferts R, Wu M, Deegan T, Fujisawa R, Tan KW, Lim CT, Basier C, Canal B, Curran JF, Drury LS, McClure AW, Roberts EL, Weissmann F, Zeisner TU, Beale R, Cowling VH, Howell M, Labib K, Diffley JFX. Biochem J 478 2481-2497 (2021)
  7. An atomistic model of the coronavirus replication-transcription complex as a hexamer assembled around nsp15. Perry JK, Appleby TC, Bilello JP, Feng JY, Schmitz U, Campbell EA. J Biol Chem 297 101218 (2021)
  8. Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate. Bobiļeva O, Bobrovs R, Kaņepe I, Patetko L, Kalniņš G, Šišovs M, Bula AL, Gri Nberga S, Borodušķis MR, Ramata-Stunda A, Rostoks N, Jirgensons A, Ta Rs K, Jaudzems K. ACS Med Chem Lett 12 1102-1107 (2021)
  9. Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first 6 months of the COVID-19 pandemic. Lubin JH, Zardecki C, Dolan EM, Lu C, Shen Z, Dutta S, Westbrook JD, Hudson BP, Goodsell DS, Williams JK, Voigt M, Sarma V, Xie L, Venkatachalam T, Arnold S, Alfaro Alvarado LH, Catalfano K, Khan A, McCarthy E, Staggers S, Tinsley B, Trudeau A, Singh J, Whitmore L, Zheng H, Benedek M, Currier J, Dresel M, Duvvuru A, Dyszel B, Fingar E, Hennen EM, Kirsch M, Khan AA, Labrie-Cleary C, Laporte S, Lenkeit E, Martin K, Orellana M, Ortiz-Alvarez de la Campa M, Paredes I, Wheeler B, Rupert A, Sam A, See K, Soto Zapata S, Craig PA, Hall BL, Jiang J, Koeppe JR, Mills SA, Pikaart MJ, Roberts R, Bromberg Y, Hoyer JS, Duffy S, Tischfield J, Ruiz FX, Arnold E, Baum J, Sandberg J, Brannigan G, Khare SD, Burley SK. Proteins 90 1054-1080 (2022)
  10. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19. Perveen S, Khalili Yazdi A, Devkota K, Li F, Ghiabi P, Hajian T, Loppnau P, Bolotokova A, Vedadi M. SLAS Discov 26 620-627 (2021)
  11. Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening. Bobrovs R, Kanepe I, Narvaiss N, Patetko L, Kalnins G, Sisovs M, Bula AL, Grinberga S, Boroduskis M, Ramata-Stunda A, Rostoks N, Jirgensons A, Tars K, Jaudzems K. Pharmaceuticals (Basel) 14 1243 (2021)
  12. Substrate Specificity of SARS-CoV-2 Nsp10-Nsp16 Methyltransferase. Benoni R, Krafcikova P, Baranowski MR, Kowalska J, Boura E, Cahová H. Viruses 13 1722 (2021)
  13. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex. Khalili Yazdi A, Li F, Devkota K, Perveen S, Ghiabi P, Hajian T, Bolotokova A, Vedadi M. SLAS Discov 26 757-765 (2021)
  14. A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2'-O methylation of its first nucleotide. Viswanathan T, Misra A, Chan SH, Qi S, Dai N, Arya S, Martinez-Sobrido L, Gupta YK. Nat Commun 12 3287 (2021)
  15. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. Kasprzyk R, Spiewla TJ, Smietanski M, Golojuch S, Vangeel L, De Jonghe S, Jochmans D, Neyts J, Kowalska J, Jemielity J. Antiviral Res 193 105142 (2021)
  16. SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms. O'Donoghue SI, Schafferhans A, Sikta N, Stolte C, Kaur S, Ho BK, Anderson S, Procter JB, Dallago C, Bordin N, Adcock M, Rost B. Mol Syst Biol 17 e10079 (2021)
  17. Anti-COVID-19 activity of some benzofused 1,2,3-triazolesulfonamide hybrids using in silico and in vitro analyses. Alzahrani AY, Shaaban MM, Elwakil BH, Hamed MT, Rezki N, Aouad MR, Zakaria MA, Hagar M. Chemometr Intell Lab Syst 217 104421 (2021)
  18. Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis. de Leon VNO, Manzano JAH, Pilapil DYH, Fernandez RAT, Ching JKAR, Quimque MTJ, Agbay JCM, Notarte KIR, Macabeo APG. J Genet Eng Biotechnol 19 104 (2021)
  19. In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. Chan WKB, Olson KM, Wotring JW, Sexton JZ, Carlson HA, Traynor JR. Sci Rep 12 5320 (2022)
  20. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2'-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Eissa IH, Alesawy MS, Saleh AM, Elkaeed EB, Alsfouk BA, El-Attar AMM, Metwaly AM. Molecules 27 2287 (2022)
  21. In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs. Elmorsy MA, El-Baz AM, Mohamed NH, Almeer R, Abdel-Daim MM, Yahya G. Environ Sci Pollut Res Int 29 12336-12346 (2022)
  22. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase. Freidel MR, Armen RS. PLoS One 16 e0246181 (2021)
  23. Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2'-O-ribose methyltransferases. Bergant V, Yamada S, Grass V, Tsukamoto Y, Lavacca T, Krey K, Mühlhofer MT, Wittmann S, Ensser A, Herrmann A, Vom Hemdt A, Tomita Y, Matsuyama S, Hirokawa T, Huang Y, Piras A, Jakwerth CA, Oelsner M, Thieme S, Graf A, Krebs S, Blum H, Kümmerer BM, Stukalov A, Schmidt-Weber CB, Igarashi M, Gramberg T, Pichlmair A, Kato H. EMBO J 41 e111608 (2022)
  24. Structural Analysis of the OC43 Coronavirus 2'-O-RNA Methyltransferase. Dostalik P, Krafcikova P, Silhan J, Kozic J, Chalupska D, Chalupsky K, Boura E. J Virol 95 e0046321 (2021)
  25. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2. Hasan M, Ashik AI, Chowdhury MB, Tasnim AT, Nishat ZS, Hossain T, Ahmed S. Inform Med Unlocked 24 100569 (2021)
  26. Finding Druggable Sites in Proteins Using TACTICS. Evans DJ, Yovanno RA, Rahman S, Cao DW, Beckett MQ, Patel MH, Bandak AF, Lau AY. J Chem Inf Model 61 2897-2910 (2021)
  27. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2. Mohammad A, Alshawaf E, Marafie SK, Abu-Farha M, Al-Mulla F, Abubaker J. Biomolecules 11 573 (2021)
  28. Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. Russ A, Wittmann S, Tsukamoto Y, Herrmann A, Deutschmann J, Lagisquet J, Ensser A, Kato H, Gramberg T. EMBO Rep 23 e55648 (2022)
  29. Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16. Klima M, Khalili Yazdi A, Li F, Chau I, Hajian T, Bolotokova A, Kaniskan HÜ, Han Y, Wang K, Li D, Luo M, Jin J, Boura E, Vedadi M. Protein Sci 31 e4395 (2022)
  30. Destruction mechanisms of ozone over SARS-CoV-2. Ataei-Pirkooh A, Alavi A, Kianirad M, Bagherzadeh K, Ghasempour A, Pourdakan O, Adl R, Kiani SJ, Mirzaei M, Mehravi B. Sci Rep 11 18851 (2021)
  31. Localization of SARS-CoV-2 Capping Enzymes Revealed by an Antibody against the nsp10 Subunit. Horova V, Landova B, Hodek J, Chalupsky K, Krafcikova P, Chalupska D, Duchoslav V, Weber J, Boura E, Klima M. Viruses 13 1487 (2021)
  32. Conserved coronavirus proteins as targets of broad-spectrum antivirals. Melo-Filho CC, Bobrowski T, Martin HJ, Sessions Z, Popov KI, Moorman NJ, Baric RS, Muratov EN, Tropsha A. Antiviral Res 204 105360 (2022)
  33. Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins. Hijikata A, Shionyu C, Nakae S, Shionyu M, Ota M, Kanaya S, Shirai T. Biophys Physicobiol 18 226-240 (2021)
  34. In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex. Liang J, Pitsillou E, Burbury L, Hung A, Karagiannis TC. Chem Phys Lett 774 138618 (2021)
  35. Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19 -associated main enzymes. Alici H, Tahtaci H, Demir K. Comput Biol Chem 98 107657 (2022)
  36. Exploring the inhibitory potential of novel bioactive compounds from mangrove actinomycetes against nsp10 the major activator of SARS-CoV-2 replication. Muhammad S, Qaisar M, Iqbal J, Khera RA, Al-Sehemi AG, Alarfaji SS, Adnan M. Chem Zvesti 76 3051-3064 (2022)
  37. Synthesis, crystal structure, potential drug properties for Coronavirus of Co(II) and Zn(II) 2-chlorobenzoate with 3-cyanopyridine complexes. Öztürkkan FE, Özdemir M, Akbaba GB, Sertçelik M, Yalçın B, Necefoğlu H, Hökelek T. J Mol Struct 1250 131825 (2022)
  38. Applying polypharmacology approach for drug repurposing for SARS-CoV2. Jamir E, Sarma H, Priyadarsinee L, Nagamani S, Kiewhuo K, Gaur AS, Rawal RK, Murugan NA, Subramanian V, Sastry GN. J Chem Sci (Bangalore) 134 57 (2022)
  39. Exploring the Catalytic Mechanism of the RNA Cap Modification by nsp16-nsp10 Complex of SARS-CoV-2 through a QM/MM Approach. Silva JRA, Urban J, Araújo E, Lameira J, Moliner V, Alves CN. Int J Mol Sci 23 300 (2021)
  40. In silico study of potential antiviral activity of copper(II) complexes with non-steroidal anti-inflammatory drugs on various SARS-CoV-2 target proteins. Geromichalou EG, Trafalis DT, Dalezis P, Malis G, Psomas G, Geromichalos GD. J Inorg Biochem 231 111805 (2022)
  41. Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex Bhardwaj A, Sharma S, Singh SK. Turk J Pharm Sci 19 93-100 (2022)
  42. SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3. Schindewolf C, Lokugamage K, Vu MN, Johnson BA, Scharton D, Plante JA, Kalveram B, Crocquet-Valdes PA, Sotcheff S, Jaworski E, Alvarado RE, Debbink K, Daugherty MD, Weaver SC, Routh AL, Walker DH, Plante KS, Menachery VD. J Virol 97 e0153222 (2023)
  43. In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. Chakraborty R, Bhattacharje G, Baral J, Manna B, Mullick J, Mathapati BS, Abraham P, J M, Hasija Y, Ghosh A, Das AK. Comput Biol Med 147 105788 (2022)
  44. Proteolytic Processing of the Coronavirus Replicase Nonstructural Protein 14 Exonuclease Is Not Required for Virus Replication but Alters RNA Synthesis and Viral Fitness. Anderson-Daniels J, Gribble J, Denison M. J Virol 96 e0084122 (2022)
  45. A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. Springstein BL, Deighan P, Grabe GJ, Hochschild A. mBio 12 e0293621 (2021)
  46. Computational investigation of potent inhibitors against SARS-CoV-2 2'-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations. Shi L, Wen Z, Song Y, Wang J, Yu D. J Mol Graph Model 117 108306 (2022)
  47. Emerging variants of SARS-CoV-2 NSP10 highlight strong functional conservation of its binding to two non-structural proteins, NSP14 and NSP16. Wang H, Rizvi SRA, Dong D, Lou J, Wang Q, Sopipong W, Su Y, Najar F, Agarwal PK, Kozielski F, Haider S. Elife 12 RP87884 (2023)
  48. Special Features of COVID-19 in the FMODB: Fragment Molecular Orbital Calculations and Interaction Energy Analysis of SARS-CoV-2-Related Proteins. Fukuzawa K, Kato K, Watanabe C, Kawashima Y, Handa Y, Yamamoto A, Watanabe K, Ohyama T, Kamisaka K, Takaya D, Honma T. J Chem Inf Model 61 4594-4612 (2021)
  49. Structural basis for SARS-CoV-2 nucleocapsid (N) protein recognition by 14-3-3 proteins. Eisenreichova A, Boura E. J Struct Biol 214 107879 (2022)
  50. The cardiac molecular setting of metabolic syndrome in pigs reveals disease susceptibility and suggests mechanisms that exacerbate COVID-19 outcomes in patients. Ziegler O, Sriram N, Gelev V, Radeva D, Todorov K, Feng J, Sellke FW, Robson SC, Hiromura M, Alexandrov BS, Usheva A. Sci Rep 11 19752 (2021)
  51. Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2. Nakayoshi T, Kato K, Kurimoto E, Oda A. Int J Mol Sci 22 9837 (2021)
  52. Virtual screening and molecular dynamics simulation for identification of natural antiviral agents targeting SARS-CoV-2 NSP10. Zhao H, Liu J, He L, Zhang L, Yu R, Kang C. Biochem Biophys Res Commun 626 114-120 (2022)
  53. A computational study on the molecular mechanisms of panduratin A as a potential inhibitor on SARS-CoV-2 protein targets. Boonserm P, Khunrae P, Sutthibutpong T. Heliyon 9 e12780 (2023)
  54. Analysis of critical protein-protein interactions of SARS-CoV-2 capping and proofreading molecular machineries towards designing dual target inhibitory peptides. Arabi-Jeshvaghani F, Javadi-Zarnaghi F, Ganjalikhany MR. Sci Rep 13 350 (2023)
  55. Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. Agrawal S, Pathak E, Mishra R, Mishra V, Parveen A, Mishra SK, Byadgi PS, Dubey SK, Chaudhary AK, Singh V, Chaurasia RN, Atri N. Comput Biol Med 149 106049 (2022)
  56. Coronavirus Inhibitors Targeting nsp16. Omer EA, Abdelfatah S, Riedl M, Meesters C, Hildebrandt A, Efferth T. Molecules 28 988 (2023)
  57. Data-driven platform for identifying variants of interest in COVID-19 virus. Ramarao-Milne P, Jain Y, Sng LMF, Hosking B, Lee C, Bayat A, Kuiper M, Wilson LOW, Twine NA, Bauer DC. Comput Struct Biotechnol J 20 2942-2950 (2022)
  58. Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors. Hassan H, Chiavaralli J, Hassan A, Bedda L, Krischuns T, Chen KY, Li ASM, Delpal A, Decroly E, Vedadi M, Naffakh N, Agou F, Mallart S, Arafa RK, Arimondo PB. RSC Med Chem 14 507-519 (2023)
  59. Identification and characterization of alternative sites and molecular probes for SARS-CoV-2 target proteins. Iyengar SM, Barnsley KK, Vu HY, Bongalonta IJA, Herrod AS, Scott JA, Ondrechen MJ. Front Chem 10 1017394 (2022)
  60. Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets. Mihalič F, Benz C, Kassa E, Lindqvist R, Simonetti L, Inturi R, Aronsson H, Andersson E, Chi CN, Davey NE, Överby AK, Jemth P, Ivarsson Y. Nat Commun 14 5636 (2023)
  61. Molecular docking with SARS-CoV-2 and potential drug property of a bioactive novel Zn(II) polymer: A combined experimental and theoretical study. Nashre-Ul-Islam SM, Borah KK, Raza MA, Öztürkkan FE. Polyhedron 233 116304 (2023)
  62. Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins. Rani R, Long S, Pareek A, Dhaka P, Singh A, Kumar P, McInerney G, Tomar S. Virology 577 1-15 (2022)
  63. nCoVDock2: a docking server to predict the binding modes between COVID-19 targets and its potential ligands. Liu K, Lu X, Shi H, Xu X, Kong R, Chang S. Nucleic Acids Res 51 W365-W371 (2023)


Quick links